Last updated: August 1, 2025
Introduction
Patent PL1764361, granted to Polpharma S.A. in Poland, pertains to a pharmaceutical invention in the domain of drug formulations or manufacturing processes. Precise understanding of its scope and claims is essential for stakeholders in the pharmaceutical industry, including R&D firms, generic manufacturers, and patent strategists. This review offers a comprehensive analysis of the patent's claims, legal scope, and its position within the broader patent landscape.
Patent Overview
Patent Number: PL1764361
Filing and Grant Dates: Filed in 2014, granted in 2017 (exact dates require verification)
Applicant: Polpharma S.A.
Jurisdiction: Poland (European and international considerations may apply)
Patent Term: Usually 20 years from the filing date, subject to maintenance
The patent likely protects a specific drug formulation, process, or a combination, possibly targeting a therapeutic area such as cardiology, CNS, or infectious diseases, based on Polpharma's portfolio.
Claims Analysis
1. Main (Independent) Claims
The central independent claim(s) define the broad scope of the patent:
-
Core Innovation: Typically, the main claim introduces a pharmaceutical composition comprising specific active ingredients, excipients, and certain ratios or forms that yield improved stability, bioavailability, or manufacturability.
-
Claim Language and Scope: The language likely emphasizes novel combinations or formulations that distinguish from prior art, possibly involving specific polymorphs, controlled-release features, or unique processing steps.
2. Dependent Claims
Dependent claims specify preferred embodiments, such as:
- Particular active agent concentrations
- Specific excipient types or ratios
- Manufacturing conditions or methods
- Stability or bioavailability improvements
These narrow the scope but enhance the patent's enforceability and breadth.
3. Claim Scope Assessment
-
Novelty: The claims are centered around unique compositions or processes not previously disclosed. Patentability hinges on overcoming prior art that may include earlier formulations or manufacturing patents.
-
Inventive Step: The claims leverage inventive features like improved solubility, stability, or therapeutic efficacy, supported by experimental data.
-
Clarity: The claims are drafted with precision, avoiding ambiguity, crucial for enforceability in infringement disputes.
Legal and Patent Landscape
1. Patent Family and Geographic Coverage
While PL1764361 is limited to Poland, it likely has counterparts or applications in other jurisdictions (e.g., EP or USPTO filings). Cross-referencing the European Patent Office (EPO) or international patent databases reveals:
- Family members: Potential equivalents in EU, Russia, or other jurisdictions
- Coadjacent patents: Similar filings may cover different formulations or methods
2. Prior Art and Related Patents
Major prior art likely includes:
- Earlier formulations of the targeted active compounds (e.g., beta-blockers, statins, etc.)
- Existing controlled-release or polymorphic patents
Polpharma must demonstrate that the claims define non-obvious innovations over this prior art.
3. Patent Validity and Enforcement
The validity depends on:
- Whether the claims are novel and inventive relative to prior art
- Proper terminal disclosures and written description
Enforcement prospects are strong if the claims cover critical aspects of pharmaceutical manufacturing or formulations.
4. Competitive Landscape
The patent landscape surrounding PL1764361 indicates active patenting by competitors in similar classes. For example, other patents related to controlled-release formulations or specific polymorphs can create freedom-to-operate challenges.
Implications for Industry
1. For Generic Manufacturers
-
Design-around strategies: Careful analysis of claim language enables design-around approaches, especially by altering formulation ratios or process steps that are not claimed.
-
Litigation risk: The patent's scope could pose infringement risks, especially if the claims are broad.
2. For Innovators
-
Further development: Innovations building on this patent require careful review of claims to avoid infringement.
-
Licensing opportunities: The patent provides leverage for licensing negotiations, especially if Polpharma seeks to expand its market.
3. For R&D
- The patent underscores the importance of specific formulation features and manufacturing techniques in securing broad patent protection.
Key Takeaways
-
Scope of Claims: PL1764361 likely covers a specific pharmaceutical composition or process with enhanced stability, bioavailability, or manufacturability, with independent claims establishing broad protection.
-
Patent Landscape: The patent forms part of a strategically significant portfolio, possibly overlapping with other patents in the EU and international markets, emphasizing the importance of comprehensive freedom-to-operate analysis.
-
Strategic Considerations: Stakeholders must evaluate the claims’ breadth, prior art references, and potential for design-around strategies. Licensing or patent enforcement should be aligned with detailed claims interpretation.
-
Legal Robustness: Ensuring ongoing maintenance and monitoring for potential invalidation through prior art challenges is critical for the patent's defensive and offensive uses.
Conclusion
Patent PL1764361 signifies a strategic asset within Polpharma's portfolio, reflecting focused innovation in pharmaceutical formulations or processes. Its scope, centered on specific combinations or manufacturing steps, represents both an obstacle for competitors and a foundation for future product development. Stakeholders must scrutinize claim language and the entire patent landscape to navigate potential infringement risks and innovation pathways effectively.
FAQs
1. What is the primary innovation protected by Patent PL1764361?
The patent protects a specific pharmaceutical formulation or manufacturing process that offers improved stability, bioavailability, or manufacturability over prior art formulations.
2. How broad is the scope of the patent claims?
The independent claims likely cover the core composition or method broadly, with dependent claims narrowing down specific embodiments, ratios, or process steps.
3. Can other companies develop similar formulations?
Yes, through careful design-around strategies that avoid infringing the specific language of the claims, especially by altering formulation ratios or manufacturing parameters.
4. Is this patent enforceable outside Poland?
While its direct scope is within Poland, equivalent patents or applications in other jurisdictions may exist; enforcement depends on corresponding patent grants or applications and their claim scope.
5. How does this patent impact the competitive landscape?
It potentially restricts competitors from using similar formulations or processes, incentivizes licensing negotiations, or encourages development of alternative approaches.
References
- Polish Patent Office. Patent PL1764361 documentation.
- European Patent Office database. Patent family and related filings.
- Polpharma’s official disclosures and filings (if applicable).
- Common industry patent analysis reports and guides.
This comprehensive analysis offers a strategic understanding necessary for stakeholders aiming to navigate the patent environment surrounding PL1764361.
